Sign In
Buy XGN
$4.54
-0.280 (-5.81%)
At Close: Jun 03, 2026
Exagen Inc. (XGN) Q4 2022 Earnings Call Transcript
07:53pm, Monday, 20'th Mar 2023
Exagen Inc. (NASDAQ:XGN ) Q4 2022 Results Conference Call March 20, 2023 4:30 PM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President and Chief Executive Officer Kamal Ada
Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates
07:04pm, Monday, 20'th Mar 2023
Exagen Inc. (XGN) delivered earnings and revenue surprises of 18.31% and 48.70%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Exagen Inc. (XGN) CEO John Aballi on Q3 2022 Results - Earnings Call Transcript
10:25pm, Monday, 14'th Nov 2022
Exagen Inc. (NASDAQ:XGN ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Ryan Douglas - IR John Aballi - President and CEO Kamal Adawi - CFO Mark Hazeltine - Chief
Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates
09:03pm, Monday, 14'th Nov 2022
Exagen Inc. (XGN) delivered earnings and revenue surprises of 38.16% and 61.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Exagen to Announce Third Quarter 2022 Financial Results on November 14, 2022
04:05pm, Monday, 31'st Oct 2022
SAN DIEGO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2022, a
Exagen Inc. (XGN) CEO Ron Rocca on Q2 2022 Results - Earnings Call Transcript
01:08pm, Saturday, 06'th Aug 2022
Exagen Inc. (NASDAQ:XGN ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Ryan Douglas - Investor Relations Ron Rocca - President and Chief Executive Officer Kamal Adaw
Exagen to Announce Second Quarter 2022 Financial Results on August 4, 2022
04:05pm, Thursday, 21'st Jul 2022
SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2022, after
Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference
08:05pm, Thursday, 26'th May 2022 GlobeNewswire Inc.
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 42nd Annual Growth
Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus
08:05pm, Monday, 16'th May 2022 GlobeNewswire Inc.
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® CTD and AVISE® Lupus are a contracted cover
Exagen Inc. (XGN) Q1 2022 Earnings Call Transcript
03:30am, Thursday, 12'th May 2022 The Motley Fool
XGN earnings call for the period ending March 31, 2022.
Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates
09:55pm, Wednesday, 11'th May 2022 Zacks Investment Research
Exagen Inc. (XGN) delivered earnings and revenue surprises of -1.69% and 2.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Exagen Inc. (XGN) CEO Ron Rocca on Q1 2022 Results - Earnings Call Transcript
08:41pm, Wednesday, 11'th May 2022
Exagen Inc. (NASDAQ:XGN ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Ryan Douglas - Investor Relations Ron Rocca - President and Chief Executive Officer Kamal Adawi
Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Test
08:06pm, Wednesday, 11'th May 2022 GlobeNewswire Inc.
SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Medicare Administrative Contractor (MAC) Noridian ha
Exagen Inc. Reports First Quarter 2022 Results
08:05pm, Wednesday, 11'th May 2022 GlobeNewswire Inc.
Records in Ordering Healthcare Providers and Adopters, Set All-Time Record for AVISE® CTD Monthly Volume in March Records in Ordering Healthcare Providers and Adopters, Set All-Time Record for AVISE�
Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates
07:34pm, Wednesday, 11'th May 2022
Exagen Inc. (XGN) delivered earnings and revenue surprises of -1.69% and 2.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
